ERBB2 and breast carcinoma: <b>Objective:</b> To evaluate the Tumor-Immune-Proliferation-Inflammation (TIPI) score as a composite biomarker for predicting pathological complete response (pCR) in human epidermal growth factor receptor 2 (HER2)-positive breast cancer treated with neoadjuvant therapy.